Armata Pharmaceuticals, Inc. 8-K

Summary

Additional U.S. Department of War funding for AP-SA02’s Phase 3 program. Armata received $3.7 million in non-dilutive funding, the first DoW funding specifically for Phase 3 execution, bringing cumulative DoW support for the program to approximately $32.4 million.

Key Figures

• Funding: $3.7M received; cumulative non-dilutive DoW funding under the award is approximately $32.4M, following $28.7M previously provided. The new funds support AP-SA02’s Phase 3 clinical program.

Investor Takeaways

• AP-SA02’s Phase 3 superiority study in complicated Staphylococcus aureus bacteremia is anticipated to start in the second half of 2026; Armata says it intends to discuss potential additional DoW support as the study advances.